SCHEMBL6774933

SCHEMBL6774933

NC(=O)c1cccc2c1c1c(O)cc(-c3ccccc3)cc1n2Cc1cccc(Cc2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 14/20 0.42
PLA2G10 O15496 10/20 0.42
ACMSD Q8TDX5 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.40
PLA2G1B P04054 2/20 0.40
PLA2G5 P39877 1/20 0.39
PLA2G2C Q5R387 1/20 0.39
PLA2G12B Q9BX93 1/20 0.39
PLA2G12A Q9BZM1 1/20 0.39
PLA2G2F Q9BZM2 1/20 0.39
PLA2G3 Q9NZ20 1/20 0.39
PLA2G2E Q9NZK7 1/20 0.39
PLA2G2D Q9UNK4 1/20 0.39
HNF4A P41235 1/20 0.37
F10 P00742 1/20 0.37
PTPN1 P18031 1/20 0.37
KLKB1 P03952 1/20 0.36
KLK1 P06870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771677 0.93 PLA2G2A (0.41) PLA2G2APLA2G10ACMSDSLCO1B1PLA2G1B
SCHEMBL6770631 0.92 PLA2G2A (0.46) PLA2G2APLA2G10ACMSDPLA2G1BF10
SCHEMBL6694433 0.92 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6775943 0.90 PLA2G2A (0.49) PLA2G2APLA2G10ACMSDSLCO1B1HNF4A
SCHEMBL6773103 0.88 PLA2G2A (0.44) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6776217 0.88 PLA2G2A (0.44) PLA2G2APLA2G10ACMSDSLCO1B1PLA2G1B
SCHEMBL6775875 0.88 PLA2G2A (0.40) PLA2G2APLA2G10PLA2G1BF10
SCHEMBL6773052 0.88 PLA2G2A (0.50) PLA2G2APLA2G1BF10
SCHEMBL6774185 0.88 TP53 (0.47) PLA2G2APLA2G1BF10KLKB1KLK1
SCHEMBL6770537 0.88 FABP3 (0.41) PLA2G2APLA2G10PLA2G1BF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed